DNER and diffuse large B-cell lymphoma: Despite the absence of FDA-approved BET inhibitors, compounds like BI 894999 have progressed to phase Ia/Ib clinical trials involving patients with advanced solid tumors and hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL) [203].